or Try an Advanced Search...

    Glucagon Like Peptide 1 Stocks List

    Symbol Grade Name % Change
    ORMP B Oramed Pharmaceuticals Inc. -1.36
    NVO C Novo Nordisk A/S -2.87
    THNR D Amplify Weight Loss Drug & Treatment ETF -0.38
    VANI F Vivani Medical, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology Medical Devices
    Related Stock Lists: Diabetes Peptide Hormones Endocrine System Insulin Medicine Anti Diabetic Drugs Biopharmaceutical Chronic Disease Diabetes Care Gastrointestinal Glucagon Growth Hormone Growth Hormone Therapy Haemophilia Hormone Therapy Hormones IBD 50 Implant Inflammation Integrated Security

    Related ETFs - A few ETFs which own one or more of the above listed Glucagon Like Peptide 1 stocks.

    Symbol Grade Name Weight
    EDEN B iShares MSCI Denmark Capped ETF 24.13
    OZEM B Roundhill GLP-1 & Weight Loss ETF 20.52
    THNR D Amplify Weight Loss Drug & Treatment ETF 14.9
    PPH B Market Vectors Pharmaceutical ETF 10.11
    IGTR A Innovator Gradient Tactical Rotation Strategy ETF 8.71
    View all Glucagon Like Peptide 1 ETFs...
    Compare ETFs
    Compare EDEN to THNR Compare PPH to IGTR Compare THNR to PPH

        Glucagon Like Peptide 1 Stocks Recent News

        Date Stock Title
        Jul 3 NVO S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
        Jul 3 NVO Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
        Jul 3 NVO Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
        Jul 3 NVO Weight-loss drugs linked to rare vision loss: Harvard study
        Jul 3 NVO Update: Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows
        Jul 3 NVO Novo Nordisk’s Ozempic, Wegovy linked to eye disorder in small study
        Jul 3 NVO Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
        Jul 3 NVO Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows
        Jul 3 NVO Should You Hold Novo Nordisk A/S (NVO) for the Long Term?
        Jul 2 NVO Novo Nordisk and Eli Lilly Slide as Biden Blasts Weight-Loss Drug Prices
        Jul 2 NVO Biden, Sanders call for obesity drug makers to cut prices
        Jul 2 NVO Fighting words: Lilly and Novo swat back at the Biden/Sanders call for lower GLP-1 prices
        Jul 2 NVO Update: Novo Nordisk, Eli Lilly Charging 'Unconscionably' High Prices, Biden, Sanders Say
        Jul 2 NVO Top Midday Stories: Tesla, GM Report Vehicle Deliveries; Biden, Sanders Say Novo Nordisk, Eli Lilly Charge 'Unconscionably' High Prices; Warner Bros. Interested in Deal With Paramount
        Jul 2 NVO Why Novo Nordisk Stock Is Slipping Today
        Jul 2 NVO Novo, Lilly Fall After Biden Slams Duo For 'Unconscionably High' Drug Prices
        Jul 2 NVO Eli Lilly history: Beyond the Ticker
        Jul 2 NVO Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
        Jul 2 NVO Novo, Lilly Slip as Biden Urges Price Cuts on Obesity Drugs
        Jul 2 NVO Big Pharma Stocks Sell Off as Biden Calls for Lower Drug Prices
        Related Industries: Biotechnology Medical Devices
        Related Stock Lists: Diabetes Peptide Hormones Endocrine System Insulin Medicine Anti Diabetic Drugs Biopharmaceutical Chronic Disease Diabetes Care Gastrointestinal Glucagon Growth Hormone Growth Hormone Therapy Haemophilia Hormone Therapy Hormones IBD 50 Implant Inflammation Integrated Security
        Glucagon Like Peptide 1

        Glucagon-like peptide 1 (GLP-1) is a hormone that is produced in the gut and released in response to food intake. It stimulates insulin secretion, suppresses glucagon secretion, slows gastric emptying, and increases satiety. GLP-1 is a key regulator of glucose homeostasis and is used as a treatment for type 2 diabetes.

        Browse All Tags